BREO ¿¤¸³Å¸ ÀǾàǰ ½ÃÀå : Áúȯº°, ¼ººÐº°, ÃÖÁ¾»ç¿ëÀÚº°, À¯Åë ä³Îº° - ¼¼°è ¿¹Ãø(2025-2030³â)
BREO Ellipta Drugs Market by Disease Condition (Asthma, COPD), Component (Corticosteroid (ICS), Long-Acting Beta2-Adrenergic Agonist), End User, Distribution Channel - Global Forecast 2025-2030
»óǰÄÚµå : 1572200
¸®¼­Ä¡»ç : 360iResearch Private Limited
¹ßÇàÀÏ : 2024³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 191 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,939 £Ü 5,699,000
PDF, Excel & 1 Year Online Access (Single User License) help
PDF ¹× Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 4,249 £Ü 6,147,000
PDF, Excel & 1 Year Online Access (2-5 User License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿Àϱâ¾÷ ³» 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 5,759 £Ü 8,332,000
PDF, Excel & 1 Year Online Access (Site License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ Áö¿ª »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 6,969 £Ü 10,083,000
PDF, Excel & 1 Year Online Access (Enterprise User License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

BREO ¿¤¸³Å¸ ÀǾàǰ ½ÃÀåÀº 2023³â¿¡ 30¾ï 5,000¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, 2024³â¿¡´Â 31¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 4.53%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 41¾ï 6,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD)°ú õ½Ä Ä¡·á¿¡ ÁÖ·Î »ç¿ëµÇ´Â BREO ¿¤¸³Å¸ ÀǾàǰ ½ÃÀåÀº °í·ÉÈ­ Àα¸ Áõ°¡, È£Èí±â ÁúȯÀÇ À¯º´·ü Áõ°¡, Á¶±â Áø´Ü ¹× Ä¡·á¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. BREO ¿¤¸³Å¸ ÀǾàǰÀÇ Çʿ伺Àº È¿°úÀûÀÌ°í »ç¿ëÇϱ⠽¬¿ì¸ç ¿À·¡ Áö¼ÓµÇ´Â È£Èí±â Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇÑ °ÍÀ¸·Î, ÇÃ·çÆ¼Ä«¼Õ°ú ºô¶õÅ×·ÑÀÇ º´¿ë¿ä¹ýÀ¸·Î Æó ±â´É °³¼± ¹× ¾ÇÈ­¸¦ ¾ïÁ¦ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù. ÁÖ¿ä ¿ëµµ´Â COPD ¹× õ½Ä Áõ»ó °ü¸®À̸ç, ÃÖÁ¾ ¿ëµµ´Â º´¿ø, Áø·á¼Ò ¹× ÀçÅÃÄ¡·á ÇöÀå¿¡ ÁýÁߵǾî ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©ÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î´Â ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ ±â¼ú ¹ßÀü, Á¤ºÎÀÇ Áö¿øÀû ±ÔÁ¦, È£Èí±â Áúȯ¿¡ Ãë¾àÇÑ ³ëÀÎ Àα¸ Áõ°¡ µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. ÃÖ±Ù ÀáÀçÀûÀÎ ºñÁî´Ï½º ±âȸ´Â ¼Ò¾Æ ÀÇ·á¿¡ ´ëÇÑ Àû¿ë È®´ë¿Í ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µÀ» À§ÇÑ ¿ø°ÝÀÇ·áÀÇ È°¿ë¿¡ ÀÖ½À´Ï´Ù. ¹ÌÃæÁ· ÀÇ·á ¼ö¿ä°¡ ÀÖ´Â ½ÅÈï ½ÃÀåÀ¸·ÎÀÇ ÁøÃâµµ »õ·Î¿î ºñÁî´Ï½º ±âȸÀÔ´Ï´Ù. ±×·¯³ª ³ôÀº Ä¡·áºñ, ºÎ½ÅÇÇÁú ½ºÅ×·ÎÀ̵忡 µû¸¥ ºÎÀÛ¿ë, Á¦³×¸¯ ÀǾàǰ°úÀÇ °æÀï µî ½ÃÀå ¼ºÀå¿¡ Á¦¾à¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¾ö°ÝÇÑ ±ÔÁ¦ ȯ°æ°ú ÀÓ»ó½ÃÇèÀÇ Çʼö ¿ä°ÇÀº ½ÃÀå ÁøÀÔ ±â°£À» ¿¬Àå½Ãŵ´Ï´Ù. ±â¼ú Çõ½Å ¹× R&D ºÐ¾ß¿¡´Â º´¿ë ¿ä¹ýÀÇ È¿°ú Çâ»ó, ȯÀÚ Áß½ÉÀÇ ÈíÀԱ⠰³¹ß, ÄÄÇöóÀ̾𽺠¹× °á°ú °³¼±À» À§ÇÑ µðÁöÅÐ Çコ ±â¼ú ÅëÇÕ µîÀÌ Æ÷ÇԵ˴ϴÙ. ¹ÙÀÌ¿À½Ã¹Ð·¯ »óȲÀ» ÀÌÇØÇϰí, Á¦Á¶ ºñ¿ë Àý°¨ Àü·«¿¡ ÅõÀÚÇϰí, ÇöÁö ¾÷ü¸¦ ÀμöÇÔÀ¸·Î½á ½ÃÀå ÀÔÁö¸¦ ´õ¿í °­È­ÇÒ ¼ö ÀÖÀ¸¸ç, BREO ¿¤¸³Å¸ ½ÃÀåÀº Àû´çÈ÷ ¼¼ºÐÈ­µÈ °æÀï ½ÃÀåÀ̸ç, ³¯·Î ÁøÈ­ÇÏ´Â Á¦¾à ȯ°æ¿¡¼­ °æÀï·ÂÀ» À¯ÁöÇϱâ À§ÇÑ R&D Ȱµ¿ÀÌ Áß¿äÇÏ°Ô ¿©°ÜÁö°í ÀÖ½À´Ï´Ù. ±ÔÁ¦ ´ç±¹ÀÇ µ¿ÇâÀ» ÆÄ¾ÇÇϰí źźÇÑ À¯Åë¸ÁÀ» ±¸ÃàÇÔÀ¸·Î½á ±â¾÷Àº ½ÃÀå ÁöÀ§¸¦ ÃÖÀûÈ­ÇÏ°í ±âÁ¸ ¼ºÀå ±âȸ¸¦ Ȱ¿ëÇÏ¿© Å« ¼ºÀåÀ» ÀÌ·ê ¼ö ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀåÀÇ Åë°è
±âÁسâ[2023] 30¾ï 5,000¸¸ ´Þ·¯
¿¹Ãø³â[2024] 31¾ï 8,000¸¸ ´Þ·¯
¿¹Ãø³â[2030] 41¾ï 6,000¸¸ ´Þ·¯
CAGR(%) 4.53%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â BREO ¿¤¸³Å¸ ÀǾàǰ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ®¸¦ °ø°³ÇÕ´Ï´Ù.

BREO ¿¤¸³Å¸ Á¦¾à ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ëÀ¸·Î º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ º¯È­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«Àû ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¿ªÀû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

Portre's Five Forces: BREO ¿¤¸³Å¸ ÀǾàǰ ½ÃÀå °ø·«À» À§ÇÑ Àü·«Àû Åø

Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ ÅøÀÔ´Ï´Ù. Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®À» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : BREO ¿¤¸³Å¸ ÀǾàǰ ½ÃÀå¿¡¼­ÀÇ ¿ÜºÎ ¿µÇâ·Â ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº BREO ¿¤¸³Å¸ ÀǾàǰ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀ̰í Àû±ØÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® BREO ¿¤¸³Å¸ ÀǾàǰ ½ÃÀå¿¡¼­°æÀï ±¸µµ ÆÄ¾Ç

BREO ¿¤¸³Å¸ ÀǾàǰ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ º¥´õÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¸ÅÃâ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­, ÅëÇÕÀÇ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÀλçÀÌÆ®À» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º BREO ¿¤¸³Å¸ ÀǾàǰ ½ÃÀå¿¡¼­ÀÇ º¥´õ ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â BREO ¿¤¸³Å¸ Á¦¾à ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ ÅøÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î º¥´õ¸¦ Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ BREO ¿¤¸³Å¸ Á¦¾à ½ÃÀå¿¡¼­ÀÇ ¼º°øÀ» À§ÇÑ Àü·« ºÐ¼® ¹× ±ÇÀå »çÇ×

BREO ¿¤¸³Å¸ ÀǾàǰ ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ÀÇ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö ÀÖµµ·Ï ÁغñÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù. :

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸°³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù. :

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÔ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå °³¿ä

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

Á¦6Àå BREO ¿¤¸³Å¸ ÀǾàǰ ½ÃÀå : º´»óº°

Á¦7Àå BREO ¿¤¸³Å¸ ÀǾàǰ ½ÃÀå : ÄÄÆ÷³ÍÆ®º°

Á¦8Àå BREO ¿¤¸³Å¸ ÀǾàǰ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

Á¦9Àå BREO ¿¤¸³Å¸ ÀǾàǰ ½ÃÀå : À¯Åë ä³Îº°

Á¦10Àå ¾Æ¸Þ¸®Ä« BREO ¿¤¸³Å¸ ÀǾàǰ ½ÃÀå

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ BREO ¿¤¸³Å¸ ÀǾàǰ ½ÃÀå

Á¦12Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« BREO ¿¤¸³Å¸ ÀǾàǰ ½ÃÀå

Á¦13Àå °æÀï ±¸µµ

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The BREO Ellipta Drugs Market was valued at USD 3.05 billion in 2023, expected to reach USD 3.18 billion in 2024, and is projected to grow at a CAGR of 4.53%, to USD 4.16 billion by 2030.

The market for BREO Ellipta drugs, utilized primarily in treating chronic obstructive pulmonary disease (COPD) and asthma, is driven by a growing aging population, rising prevalence of respiratory ailments, and heightened awareness regarding early diagnosis and treatment. These medications provide a combination therapy approach of fluticasone and vilanterol, aimed at improving lung function and reducing exacerbations. The necessity for BREO Ellipta drugs stems from the increasing demand for effective, easy-to-use, and long-acting respiratory treatments. The major applications include symptom management in COPD and asthma, whereas end-use is concentrated in hospitals, clinics, and homecare settings. Key factors contributing to the growth of this market include technological advancements in drug delivery systems, supportive government regulations, and an expanding geriatric population more susceptible to respiratory diseases. Recent potential opportunities lie in extending application to pediatric care and exploiting telemedicine for remote patient monitoring. Expansion into emerging markets with unmet medical needs presents another opportunity. However, the market faces limiting factors, such as high treatment costs, side effects associated with corticosteroids, and competition from generic drug alternatives, which may restrain growth. Additionally, stringent regulatory environments and the essential requirement for clinical trials prolong market entry timelines. Areas for innovation and research prominently involve enhancing the efficacy of combination therapies, developing patient-centric inhalers, and integrating digital health technologies to improve compliance and outcomes. Understanding the biosimilars landscape, investing in strategies to reduce production costs, and acquisitions of local players can further bolster market presence. The nature of the BREO Ellipta market is moderately fragmented and competitive, emphasizing research and development activities to maintain a competitive edge in the ever-evolving pharmaceuticals landscape. By navigating regulatory pathways and building robust distribution networks, businesses can optimize their market position and leverage existing opportunities for substantial growth.

KEY MARKET STATISTICS
Base Year [2023] USD 3.05 billion
Estimated Year [2024] USD 3.18 billion
Forecast Year [2030] USD 4.16 billion
CAGR (%) 4.53%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving BREO Ellipta Drugs Market

The BREO Ellipta Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Porter's Five Forces: A Strategic Tool for Navigating the BREO Ellipta Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the BREO Ellipta Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the BREO Ellipta Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the BREO Ellipta Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the BREO Ellipta Drugs Market

A detailed market share analysis in the BREO Ellipta Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the BREO Ellipta Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the BREO Ellipta Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the BREO Ellipta Drugs Market

A strategic analysis of the BREO Ellipta Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the BREO Ellipta Drugs Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca plc, Boehringer Ingelheim International GmbH, CHIESI Farmaceutici S.p.A., Cipla Limited, GlaxoSmithKline plc, Hikma Pharmaceuticals PLC, Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Novartis AG, Orion Corporation, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the BREO Ellipta Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

6. BREO Ellipta Drugs Market, by Disease Condition

7. BREO Ellipta Drugs Market, by Component

8. BREO Ellipta Drugs Market, by End User

9. BREO Ellipta Drugs Market, by Distribution Channel

10. Americas BREO Ellipta Drugs Market

11. Asia-Pacific BREO Ellipta Drugs Market

12. Europe, Middle East & Africa BREO Ellipta Drugs Market

13. Competitive Landscape

Companies Mentioned

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â